Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.

MLA

Anker, Stefan D., et al. “Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.” Circulation, vol. 143, no. 4, Jan. 2021, pp. 337–49. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.120.051824.

APA

Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., Bocchi, E. A., Ponikowski, P., Perrone, S. V., Januzzi, J. L., Verma, S., Böhm, M., Ferreira, J. P., Pocock, S. J., Zannad, F., & Packer, M. (2021). Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation, 143(4), 337–349. https://doi.org/10.1161/CIRCULATIONAHA.120.051824

Chicago

Anker, Stefan D, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, et al. 2021. “Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.” Circulation 143 (4): 337–49. doi:10.1161/CIRCULATIONAHA.120.051824.